



Supplemental Figure 1. Correlation between SUVmean and SUVmax of all evaluable tumor lesions at baseline (r = 0.99, P < 0.0001).



Supplemental Figure 2. 89Zr-bevacizumab uptake in healthy organs at baseline.



Supplemental Figure 3. Correlation between time on treatment and baseline tumor tracer uptake (r = 0.63, P = 0.02).